Sue Foxley

Sue leads a dynamic programme of research at Bidwells. Working with her colleague Mark Callender, she is particularly focused on the real estate implications of the science and technology sector.

In addition to overseeing Bidwells long running and detailed market data, Sue has built a programme of research, collaborating with academics and consultants, such as YouGov and Henley Business School as well as specialist scientific advisors, to deliver an in depth understanding of the science and tech markets.

Sue gave a talk at the Bisnow Life Sciences conference alongside Saul Western, speaking on the evolving life sciences market.

If you’d like to hear more, browse our Arc Market Databook papers > https://www.bidwells.co.uk/what-we-do/arc-market-databook/

Experience

Science & Technology

01

Science & Technology

The number one UK advisor to S&T for the last 50 years

Our insights

Reports & Briefings 13.03.26

A follow-up to our Driving Innovation at Speed report, published to coincide with the start of the 2026 Formula 1 season.

The Biggest Reset in F1 History with the UK Motorsport Cluster at its centre.

Image of 1400 x 500 NO TEXT Investment for Growth Science and Tech Graphics

Reports & Briefings 05.06.25

Life science spinouts are key to unlocking the UK’s global scientific potential.

Investment for Growth: Now is the time to go big

Image of WEB 2886 Investment for Growth Report Graphics

Reports & Briefings 20.05.25

Is Britain Ready to Grow Again?

Investment for Growth: The case for micro-economic reforms

Blog 23.01.25

The UK Government’s plan to expand AI computing capacity 20-fold by 2030 highlights the transformative potential of emerging technologies.

Powering a Productive UK

Blog 16.11.24

Milton Keynes is emerging as one of the UK’s most vibrant tech hubs, boasting the second-highest density of tech employment among UK cities (excluding London), only behind Reading.

How Tech Growth is Redefining Real Estate in Milton Keynes

Report 2024

Significant real estate lettings tell the story of a country highly attractive to global giants from Apple and Amazon to Moderna and MSD, but which struggles to nurture and retain our own innovative SMEs to scale. This is not to say the UK has an unimpressive record.

Commercialising Science